HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    

Zacks Education
Visit Zacks' Education section for investing guides and other free resources to make you a better investor.
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Small Cap Trader
Strategic Investor
Surprise Trader
Top 10 Stocks
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive


SCR: Simcere Pharmaceutical Group - Full Company Report Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Full Company Report |  Estimates |  Brokerage Recommendations |  Comparison to Industry |  Insiders |  Brokerage Reports |  Zacks Equity Research   |  Annual Report
SIMCERE PHARMACEUTICAL GROUP (NYSE)
SCR 7.23 -0.03 (-0.41%) Vol.  222,305 16:03 ET
SIMCERE PHARMACEUTICAL GROUP is a leading manufacturer and supplier of branded generic pharmaceuticals in the rapidly growing China market. Their strategic focus is to introduce first to market generic and innovative pharmaceuticals for the treatment of diseases with high incidence and or mortality rate and for which there is a clear demand for more effective pharmacotherapy.

 General Information
SIMCERE PHARMAC
No 699-18 Xuan Wu Avenue
Xuan Wu District
Nanjing, - 210042
Phone: 86 25 8556 6666
Fax: 86 25 8547 1729
Web: www.simcere.com
Email: zhaozhigang@simcere.com
 
Industry MED-GENERIC DRG
Sector: Medical
 
Fiscal Year End December
Last Reported Quarter 09/30/09
Next EPS Date 03/11/2010
 
 Price and Volume Information
Zacks Rank
Yesterday's Close 7.26
52 Week High 9.98
52 Week Low 4.76
Beta 1.35
20 Day Moving Average 87,094.90
Target Price Consensus 8.85
 
 % Price Change
4 Week -6.59
12 Week -5.37
YTD 0.84
 % Price Change Relative to S&P 500
4 Week -7.60
12 Week -10.78
YTD -16.55
 Share Information
Shares Outstanding (millions) 56.84
Market Capitalization (millions) 410.94
Short Ratio 6.40
Last Split Date N/A
 Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio 0.00
Change in Payout Ratio 0.00
Last Dividend Payout / Amount NA / $0.00

 EPS Information
Current Quarter EPS Consensus Estimate 0.08
Current Year EPS Consensus Estimate 0.42
Estimated Long-Term EPS Growth Rate 10.00
Next EPS Report Date 03/11/2010
 Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell) 2.46
30 Days Ago 2.46
60 Days Ago 2.46
90 Days Ago 2.46

 Fundamental Ratios
 P/E
Current FY Estimate: 18.15
Trailing 12 Months: 19.54
PEG Ratio 1.82
 EPS Growth
vs. Previous Year -81.82%
vs. Previous Quarter -55.56%
 Sales Growth
vs. Previous Year 0.41%
vs. Previous Quarter: 4.62%
 Price Ratios
Price/Book 1.32
Price/Cash Flow 7.48
Price / Sales 1.58
 ROE
09/30/09 7.04
06/30/09 10.29
03/31/09 12.84
 ROA
09/30/09 5.61
06/30/09 8.23
03/31/09 10.32
 Current Ratio
09/30/09 2.81
06/30/09 3.40
03/31/09 5.32
 Quick Ratio
09/30/09 2.58
06/30/09 3.14
03/31/09 4.98
 Operating Margin
09/30/09 8.64
06/30/09 12.84
03/31/09 15.99
 Net Margin
09/30/09 11.62
06/30/09 15.65
03/31/09 19.98
 Pre-Tax Margin
09/30/09 11.62
06/30/09 15.65
03/31/09 19.98
 Book Value
09/30/09 5.49
06/30/09 5.33
03/31/09 5.09
 Inventory Turnover
09/30/09 3.04
06/30/09 3.33
03/31/09 3.61
 Debt-to-Equity
09/30/09 0.03
06/30/09 0.03
03/31/09 0.03
 Debt to Capital
09/30/09 2.61
06/30/09 5.09
03/31/09 4.65

 
About Zacks | Advertise | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2009 Zacks Investment Research